Merck’s EMEA Advance Biotech Grant Program

Merck’s EMEA Advance Biotech Grant Program is designed to support emerging biotech companies on the forefront of innovative drug development. Targeted at biotechs with a focus on novel modalities and therapeutics, this program aids companies with at least one biologic in the pipeline, particularly those working on mAbs, ADCs, mRNA, gene therapy, cell therapy, and vaccines.

The program offers significant prizes: the winner receives €148,400 in bioprocessing technologies, consultation with M Ventures, contract testing services, and a one-year Emprove® Premium subscription. Finalists are awarded €20,000 in bioprocessing technologies.

This grant provides crucial support to help emerging biotechs advance their drug development and bring the next generation of therapies to market.

Final day to submit your application: September 9, 2024.

For more information, click here.

EVENT FINISHED